X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (85446) 85446
Newspaper Article (7605) 7605
Newsletter (7195) 7195
Publication (5651) 5651
Magazine Article (1481) 1481
Book Review (1217) 1217
Book Chapter (706) 706
Book / eBook (388) 388
Trade Publication Article (369) 369
Web Resource (212) 212
Conference Proceeding (152) 152
Dissertation (120) 120
Government Document (106) 106
Transcript (46) 46
Reference (45) 45
Data Set (21) 21
Report (13) 13
Streaming Video (13) 13
Paper (11) 11
Journal / eJournal (6) 6
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (58684) 58684
female (31124) 31124
male (29158) 29158
index medicus (28807) 28807
vitamin d (22009) 22009
middle aged (16973) 16973
adult (15556) 15556
animals (13931) 13931
aged (13849) 13849
research (11267) 11267
alfacalcidol (9916) 9916
calcifediol (9848) 9848
vitamins (9332) 9332
risk factors (9293) 9293
health aspects (8802) 8802
dietary supplements (8084) 8084
care and treatment (6809) 6809
oxidative stress (6075) 6075
vitamin e (5946) 5946
cancer (5864) 5864
treatment outcome (5850) 5850
adolescent (5678) 5678
child (5514) 5514
vitamin d - therapeutic use (5397) 5397
osteoporosis (5304) 5304
rats (5263) 5263
prevention (5190) 5190
endocrinology & metabolism (5042) 5042
analysis (5008) 5008
nutrition & dietetics (4897) 4897
vitamin c (4861) 4861
medicine, general & internal (4786) 4786
risk (4784) 4784
diet therapy (4714) 4714
medical research (4648) 4648
vitamin b (4595) 4595
antioxidants (4593) 4593
vitamins - therapeutic use (4384) 4384
pharmacology & pharmacy (4358) 4358
diet (4293) 4293
medicine (4236) 4236
therapy (4214) 4214
vitamin-d (4185) 4185
vitamin-e (4111) 4111
studies (4099) 4099
aged, 80 and over (4089) 4089
metabolism (4071) 4071
physiological aspects (4057) 4057
oncology (3978) 3978
vitamin deficiency (3913) 3913
calcium (3905) 3905
vitamin a (3903) 3903
vitamin d - blood (3824) 3824
nutrition (3811) 3811
mice (3799) 3799
vitamin e - therapeutic use (3737) 3737
drug therapy (3691) 3691
pregnancy (3614) 3614
infant (3555) 3555
diabetes (3499) 3499
mortality (3497) 3497
disease (3462) 3462
child, preschool (3404) 3404
pediatrics (3379) 3379
patients (3353) 3353
medicine, experimental (3267) 3267
time factors (3165) 3165
clinical trials (3145) 3145
vitamin d - analogs & derivatives (3127) 3127
supplementation (3091) 3091
children (3016) 3016
medicine & public health (3004) 3004
vitamin b 12 - therapeutic use (2991) 2991
research article (2975) 2975
prevalence (2963) 2963
article (2936) 2936
prospective studies (2935) 2935
administration, oral (2926) 2926
drug therapy, combination (2926) 2926
women (2924) 2924
urology & nephrology (2915) 2915
double-blind method (2809) 2809
biochemistry & molecular biology (2784) 2784
young adult (2721) 2721
vitamin d - administration & dosage (2709) 2709
inflammation (2700) 2700
dose-response relationship, drug (2619) 2619
bone density (2618) 2618
proteins (2612) 2612
warfarin (2585) 2585
hematology (2580) 2580
antioxidants - therapeutic use (2577) 2577
abridged index medicus (2569) 2569
reports (2549) 2549
follow-up studies (2469) 2469
apoptosis (2411) 2411
infant, newborn (2407) 2407
diagnosis (2395) 2395
medicine, research & experimental (2360) 2360
surgery (2340) 2340
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (237) 237
Online Resources - Online (36) 36
Collection Dvlpm't (Acquisitions) - Vendor file (13) 13
Collection Dvlpm't (Acquisitions) - Closed Orders (11) 11
UTL at Downsview - May be requested (11) 11
UofT at Mississauga - Stacks (5) 5
UofT at Scarborough - Stacks (5) 5
Gerstein Science - Reference (4) 4
Baycrest Hospital - Wellness Library (2) 2
Chemistry (A D Allen) - Stacks (2) 2
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (2) 2
Gerstein Science - May be requested in 6-10 wks (2) 2
Gerstein Science - Periodical Stacks (2) 2
New College (Ivey) - Stacks (2) 2
OISE - Reference (2) 2
Providence Healthcare - Reference (2) 2
Providence Healthcare - Stacks (2) 2
Scarborough Hospital - General (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
Thomas Fisher Rare Book - Rare Book (2) 2
Dentistry (Harry R Abbott) - Withdrawn (1) 1
Gerstein Science - Bindery (1) 1
Humber River Regional Hospital - Church Stacks (1) 1
Markham Stouffville Hospital - Stacks (1) 1
OISE - Audio Visual (1) 1
OISE - Stacks (1) 1
OISE - Theses (1) 1
Robarts - Reference (1) 1
Robarts - Stacks (1) 1
Scarborough Hospital - Birchmount (1) 1
Scarborough Hospital - Online (1) 1
St Josephs Health Centre - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
Toronto East General Hospital - Stacks (1) 1
Trinity College (John W Graham) - Reference (1) 1
Trinity College (John W Graham) - Stacks (1) 1
University Archives - Archives (1) 1
University College (Laidlaw) - Stacks (1) 1
UofT at Scarborough - May be requested in 6-10 wks (1) 1
Victoria University E.J. Pratt - Storage (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (92748) 92748
German (2825) 2825
Russian (1937) 1937
French (1739) 1739
Japanese (889) 889
Italian (786) 786
Spanish (667) 667
Polish (409) 409
Chinese (181) 181
Portuguese (156) 156
Danish (142) 142
Dutch (132) 132
Hungarian (114) 114
Czech (109) 109
Turkish (94) 94
Swedish (93) 93
Ukrainian (77) 77
Norwegian (67) 67
Romanian (67) 67
Korean (63) 63
Bulgarian (55) 55
Slovak (34) 34
Croatian (33) 33
Finnish (29) 29
Hebrew (27) 27
Serbian (27) 27
Arabic (16) 16
Persian (11) 11
Slovenian (10) 10
Afrikaans (6) 6
Icelandic (6) 6
Bosnian (3) 3
Lithuanian (3) 3
Welsh (2) 2
Belarusian (1) 1
Greek (1) 1
Hindi (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e44S - e88S
Background: The objective of this article is to summarize the published literature concerning the pharmacokinetics and pharmacodynamics of oral anticoagulant... 
GAMMA-CARBOXYGLUTAMIC ACID | INTRAVENOUS PHYTONADIONE VITAMIN-K-1 | FACTOR-XA INHIBITOR | VENOUS LIMB GANGRENE | EUROPEAN CONCERTED ACTION | LOW-INTENSITY WARFARIN | RESPIRATORY SYSTEM | VITAMIN-K ANTAGONISTS | TOTAL HIP-REPLACEMENT | INTERNATIONAL NORMALIZED RATIO | NONVALVULAR ATRIAL-FIBRILLATION | CRITICAL CARE MEDICINE | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | United States | Humans | Pyridines - pharmacokinetics | Antithrombins - administration & dosage | Thiophenes - administration & dosage | Dabigatran | Antithrombins - pharmacokinetics | Dose-Response Relationship, Drug | Rivaroxaban | Pyridines - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Benzimidazoles - administration & dosage | Thrombosis - blood | Thrombosis - prevention & control | Benzimidazoles - adverse effects | Morpholines - adverse effects | Pyridines - administration & dosage | Administration, Oral | Morpholines - administration & dosage | Benzimidazoles - pharmacokinetics | Anticoagulants - adverse effects | Evidence-Based Medicine | Factor Xa - metabolism | Thiophenes - pharmacokinetics | Vitamin K - blood | Antithrombins - adverse effects | Anticoagulants - pharmacokinetics | Thrombosis - drug therapy | Morpholines - pharmacokinetics | Practice Guidelines as Topic | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e326S - e350S
Background: This guideline addresses the management of patients who are receiving anticoagulant or antiplatelet therapy and require an elective surgery or... 
VITAMIN-K-ANTAGONISTS | PERCUTANEOUS CORONARY INTERVENTION | PROSTHETIC HEART-VALVES | LOW-DOSE ASPIRIN | RESPIRATORY SYSTEM | MOLECULAR-WEIGHT HEPARIN | ORAL ANTICOAGULANT-THERAPY | TRANEXAMIC ACID MOUTHWASH | NONVALVULAR ATRIAL-FIBRILLATION | INTERNATIONAL NORMALIZED RATIO | DRUG-ELUTING STENTS | CRITICAL CARE MEDICINE | Perioperative Care | United States | Humans | Postoperative Complications - blood | Postoperative Complications - prevention & control | Aspirin - pharmacokinetics | Angioplasty, Balloon, Coronary | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Fibrinolytic Agents - pharmacokinetics | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - pharmacokinetics | Postoperative Complications - drug therapy | Thrombosis - blood | Thrombosis - prevention & control | Stents | Platelet Aggregation Inhibitors - adverse effects | Drug Administration Schedule | Atrial Fibrillation - drug therapy | Heart Valve Prosthesis | Risk Factors | Atrial Fibrillation - complications | Evidence-Based Medicine | Atrial Fibrillation - blood | Fibrinolytic Agents - administration & dosage | Thrombosis - drug therapy | Elective Surgical Procedures | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e152S - e184S
Background: High-quality anticoagulation management is required to keep these narrow therapeutic index medications as effective and safe as possible. This... 
COMPUTERIZED DECISION-SUPPORT | INTENSITY WARFARIN THERAPY | DEFINITE ANTIPHOSPHOLIPID SYNDROME | RESPIRATORY SYSTEM | PROTHROMBIN COMPLEX CONCENTRATE | MOLECULAR-WEIGHT HEPARIN | DEEP-VEIN THROMBOSIS | INTERNATIONAL NORMALIZED RATIO | NONVALVULAR ATRIAL-FIBRILLATION | ACUTE VENOUS THROMBOEMBOLISM | ORAL VITAMIN-K | CRITICAL CARE MEDICINE | United States | Humans | Decision Support Systems, Clinical | Heparin - therapeutic use | Hemorrhage - prevention & control | Long-Term Care | Heparin - adverse effects | Heparin - pharmacokinetics | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Drug Interactions | Societies, Medical | Fibrinolytic Agents - pharmacokinetics | Drug-Related Side Effects and Adverse Reactions | Fibrinolytic Agents - therapeutic use | Thrombosis - blood | Thrombosis - prevention & control | Patient Education as Topic | Polysaccharides - therapeutic use | Drug Administration Schedule | Administration, Oral | Hemorrhage - therapy | Polysaccharides - adverse effects | Evidence-Based Medicine | Randomized Controlled Trials as Topic | International Normalized Ratio | Thrombosis - drug therapy | Hemorrhage - chemically induced | Infusions, Intravenous | Self Care | Polysaccharides - pharmacokinetics | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e1S - e23S
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e419S - e496S
Background: This article addresses the treatment of VTE disease. Methods: We generated strong (Grade 1) and weak (Grade 2) recommendations based on... 
RIGHT-VENTRICULAR DYSFUNCTION | RECURRENT VENOUS THROMBOEMBOLISM | TISSUE-PLASMINOGEN-ACTIVATOR | RESPIRATORY SYSTEM | ACUTE PULMONARY-EMBOLISM | MOLECULAR-WEIGHT HEPARIN | VENA-CAVA FILTER | ORAL ANTICOAGULANT-THERAPY | INTRAVENOUS UNFRACTIONATED HEPARIN | LONG-TERM TREATMENT | DEEP-VEIN-THROMBOSIS | CRITICAL CARE MEDICINE | Venous Thrombosis - diagnosis | Pulmonary Embolism - prevention & control | United States | Humans | Venous Thrombosis - blood | Heparin, Low-Molecular-Weight - adverse effects | Hemorrhage - prevention & control | Long-Term Care | Heparin, Low-Molecular-Weight - therapeutic use | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Fibrinolytic Agents - therapeutic use | Venous Thrombosis - prevention & control | Polysaccharides - therapeutic use | Drug Administration Schedule | Venous Thrombosis - drug therapy | Administration, Oral | Risk Factors | Polysaccharides - adverse effects | Anticoagulants - therapeutic use | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Pulmonary Embolism - blood | International Normalized Ratio | Diagnostic Imaging | Pulmonary Embolism - diagnosis | Pulmonary Embolism - drug therapy | Hemorrhage - chemically induced | Infusions, Intravenous | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e531S - e575S
Background: The risk of stroke varies considerably across different groups of patients with atrial fibrillation (AF). Antithrombotic prophylaxis for stroke is... 
DIRECT-CURRENT CARDIOVERSION | STROKE PREVENTION | RESPIRATORY SYSTEM | CLOPIDOGREL PLUS ASPIRIN | ORAL ANTICOAGULANT-THERAPY | RISK STRATIFICATION SCHEMES | MAJOR VASCULAR EVENTS | PULMONARY-VEIN ABLATION | ACUTE CORONARY SYNDROME | ECHOCARDIOGRAPHY-GUIDED CARDIOVERSION | ANTIARRHYTHMIC-DRUG THERAPY | CRITICAL CARE MEDICINE | Ticlopidine - therapeutic use | Humans | Electric Countershock | Hemorrhage - prevention & control | Dabigatran | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Ticlopidine - adverse effects | Aspirin - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | beta-Alanine - analogs & derivatives | Benzimidazoles - therapeutic use | Stroke - prevention & control | beta-Alanine - adverse effects | Administration, Oral | Atrial Fibrillation - drug therapy | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Ticlopidine - analogs & derivatives | Atrial Fibrillation - blood | International Normalized Ratio | Stroke - blood | Atrial Flutter - complications | Atrial Flutter - drug therapy | Hemorrhage - chemically induced | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e737S - e801S
Background: Neonates and children differ from adults in physiology, pharmacologic responses to drugs, epidemiology, and long-term consequences of thrombosis.... 
INFERIOR VENA-CAVA | TISSUE-PLASMINOGEN-ACTIVATOR | ARTERIAL ISCHEMIC-STROKE | RESPIRATORY SYSTEM | CEREBRAL SINOVENOUS THROMBOSIS | ACUTE LYMPHOBLASTIC-LEUKEMIA | LOW-MOLECULAR-WEIGHT | DEEP-VEIN THROMBOSIS | HEPARIN-INDUCED THROMBOCYTOPENIA | SICKLE-CELL-DISEASE | HOMOZYGOUS PROTEIN-C | CRITICAL CARE MEDICINE | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Humans | Upper Extremity Deep Vein Thrombosis - blood | Child, Preschool | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Upper Extremity Deep Vein Thrombosis - prevention & control | Hemorrhage - prevention & control | Secondary Prevention | Heparin - adverse effects | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Cardiac Catheterization | Vitamin K - antagonists & inhibitors | Societies, Medical | Platelet Aggregation Inhibitors - administration & dosage | Renal Veins | Thrombosis - blood | Thrombosis - prevention & control | Child | Infant, Newborn | Platelet Aggregation Inhibitors - adverse effects | Upper Extremity Deep Vein Thrombosis - drug therapy | Drug Administration Schedule | Risk Factors | Cooperative Behavior | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Interdisciplinary Communication | Thrombosis - etiology | Blood Coagulation Tests | Fibrinolytic Agents - administration & dosage | Thrombosis - drug therapy | Hemorrhage - chemically induced | Heparin, Low-Molecular-Weight - administration & dosage | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e576S - e600S
Background: Antithrombotic therapy in valvular disease is important to mitigate thromboembolism, but the hemorrhagic risk imposed must be considered. Methods:... 
RESPIRATORY SYSTEM | CRITICAL CARE MEDICINE | Heart Valve Diseases - blood | Mitral Valve | Thrombosis - complications | Ductus Arteriosus, Patent - drug therapy | Humans | Postoperative Complications - blood | Postoperative Complications - prevention & control | Stroke - complications | Hemorrhage - prevention & control | Rheumatic Heart Disease - blood | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Ductus Arteriosus, Patent - blood | Thromboembolism - prevention & control | Aspirin - adverse effects | Heart Valve Diseases - complications | Fibrinolytic Agents - therapeutic use | Rheumatic Heart Disease - drug therapy | Rheumatic Heart Disease - complications | Aspirin - therapeutic use | Thromboembolism - drug therapy | Postoperative Complications - drug therapy | Thrombosis - blood | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Catheterization | Heart Atria | Heart Valve Prosthesis | Risk Factors | Ductus Arteriosus, Patent - complications | Combined Modality Therapy | Evidence-Based Medicine | Stroke - blood | Thromboembolism - blood | Heart Valve Diseases - drug therapy | Thrombosis - drug therapy | Hemorrhage - chemically induced | Thrombolytic Therapy - adverse effects | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
JAMA, ISSN 0098-7484, 04/2015, Volume 313, Issue 13, pp. 1325 - 1335
Journal Article
JAMA, ISSN 0098-7484, 02/2012, Volume 307, Issue 7, pp. 674 - 684
Journal Article